Journal article
The rationale and design of the Beta‐blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study
Abstract
AIMS: The Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study aims to determine the feasibility of a large-scale randomized controlled trial with clinical endpoints comparing the beta-blocking agent carvedilol with placebo in patients receiving dialysis.
METHODS: The BLOCADE Feasibility Study is a randomized, double-blind, placebo-controlled, parallel group feasibility study comparing the beta-blocking agent …
Authors
Roberts MA; Pilmore HL; Ierino FL; Badve SV; Cass A; Garg AX; Hawley CM; Isbel NM; Krum H; Pascoe EM
Journal
Nephrology, Vol. 20, No. 3, pp. 140–147
Publisher
Wiley
Publication Date
3 2015
DOI
10.1111/nep.12362
ISSN
1320-5358
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Adrenergic beta-AntagonistsAustraliaCarbazolesCardiovascular DiseasesCarvedilolClinical ProtocolsDouble-Blind MethodFeasibility StudiesFemaleHumansKidney Failure, ChronicMaleMedication AdherenceMiddle AgedNew ZealandPatient SelectionPeritoneal DialysisPropanolaminesRenal DialysisResearch DesignSample SizeTime FactorsTreatment Outcome